

TennCare Pharmacy Advisory Committee Meeting

August 11, 2022, 9:30 AM - 3:30 PM CST

Microsoft Teams Meeting: [Click here to join the meeting](#)

Meeting Phone Number and Conference ID: +1 (952) 222-7450, 369 149 648+

Welcome and Introduction of Members	Chairman Capparelli
Approval of Minutes from Previous Meeting	Chairman Capparelli
Auto-Exempt Subcommittee Updates	Obiageli Nnodu, PharmD
Follow-up Items from Previous Meeting	John Brown, PharmD, Obiageli Nnodu, PharmD
TennCare Update	David Collier, MD
TennCare Pharmacy Update	Renee Williams-Clark, PharmD
Public Testimony	
New Drug Approvals and Drug Class Reviews	John Brown, PharmD, Obiageli Nnodu, PharmD

New Drug Approvals

BYLVAY	LIVTENCITY	REZUROCK	TARPEYO
LIVMARLI	OPZELURA	SKYTROFA	TAVNEOS

TennCare Pharmacy Initiatives (Drug Class Reviews)

- Standard Review
 - Gaucher's Disease Agents
 - Lambert-Eaton Myasthenic Syndrome (LEMS)
 - Oncology Agents*
 - Breast cancer
 - Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) Inhibitors
 - Prostate cancer
 - Leukemia and Lymphoma
 - Myelofibrosis
 - Multiple myeloma
 - Non-Small Cell Lung Cancer
 - Kinase Inhibitors
 - Rare Cancers and Miscellaneous Agents
 - Skin Cancers
 - Tropomyosin Receptor Kinase (TRK) Inhibitors
 - Sickle Cell Disease

*Oncology Agents will remain as a single class on the PDL; agents have been divided into subclasses for review.

- Abbreviated Review**
 - Gastrointestinal
 - Antidiarrheals
 - Miscellaneous
 - Hereditary Tyrosinemia Agents
 - Oral Copper Chelators
 - Oral Iron Chelators
 - Otics
 - Miscellaneous Otics
 - Otic Quinolones
 - Otic Steroid/Antibiotic Combinations

Review of Grayed Out Packet from Previous Meeting	Obiageli Nnodu, PharmD
Adjournment	

** - Identified drug classes will undergo a streamlined review due to no professional guideline updates or significant (if any) criteria changes